| Rinvoq (upadacitinib) / AbbVie |
ACTRN12622000032752p: A phase 4, single-arm, open-label treatment, descriptive study of upadacitinib effectiveness assessed by magnetic resonance imaging (MRI) changes in the hand/wrist and clinical response outcomes in participants with rheumatoid arthritis on methotrexate and who are biologic naïve. |
|
|
| Not yet recruiting | 4 | 30 | | | Emeritus Research Pty Ltd, AbbVie Pty Ltd | rheumatoid arthritis | | | | |
INDUCE, ACTRN12625000861459: Upadacitinib versus Oral Corticosteroid for Induction of Transmural Remission in Moderate to Severe Ulcerative Colitis and Crohn’s Disease Flares -
|
|
|
| Not yet recruiting | 4 | 80 | | | Mater Misericordiae Ltd, Mater Misericordiae Ltd | Inflammatory Bowel Disease, Ulcerative Colitis, Crohn's Disease | | | | |
2020-005518-16: U3P study - Upadacitinib in Psoriatic Arthritis Pain Processing |
|
|
| Ongoing | 4 | 20 | Europe | Prolonged-release tablet, RINVOQ 15mg Retardtabletten | Universitätsklinikum Erlangen, Abbvie | Psoriatic arthritis Psoriasisarthritis, Psoriatic arthritis, Diseases [C] - Immune System Diseases [C20] | | | | |
ACTRN12622000032752: A phase 4, single-arm, open-label treatment, descriptive study of upadacitinib effectiveness assessed by magnetic resonance imaging (MRI) changes in the hand/wrist and clinical response outcomes in participants with rheumatoid arthritis on methotrexate and who are biologic naïve. |
|
|
| Terminated | 4 | 30 | | | Emeritus Research Pty Ltd, AbbVie Pty Ltd | rheumatoid arthritis | | | | |
NCT05153200: Early Changes in Pain, Disease Activity, and Ultrasound Evidence of Inflammatory Synovitis in Patients Receiving JAK-inhibitor vs. TNF-inhibitor Therapy for Active Rheumatoid Arthritis: A Feasibility Study. |
|
|
| Not yet recruiting | 4 | 40 | NA | Upadacitinib, Rinvoq, Adalimumab, Idacio | Ottawa Hospital Research Institute, The Ottawa Hospital, University of Ottawa | Rheumatoid Arthritis | 06/23 | 06/23 | | |
DermAtOmics-II, NCT06366932: Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models |
|
|
| Recruiting | 4 | 150 | Europe | Second-line systemic treatment, Dupilumab, Tralokinumab, Upadacitinib, Baricitinib, Abrocitinib, Folllow-up of second-line systemic treatment already started | Instituto de Investigación Hospital Universitario La Paz | Atopic Dermatitis | 09/25 | 09/25 | | |
ChiCTR2200066260: Efficacy and safety of upadacitinib in patients over 12 years old with moderate to severe atopic dermatitis after poor response to dupilumab |
|
|
| Not yet recruiting | 4 | 73 | | No intervention | Shenzhen Second People's Hospital; Shenzhen Second People's Hospital, Self-financing | Atopic dermatitis | | | | |
ChiCTR2200063335: Efficacy and safety of upadacitinib in the treatment of moderate to severe atopic dermatitis |
|
|
| Not yet recruiting | 4 | 64 | | Upadacitinib + TCS ;Cyclosporine +TCS | Longgang district Central Hospital; Longgang district Central Hospital, self-funded | atopic dermatitis | | | | |
| Completed | 4 | 841 | US | Upadacitinib, Rinvoq, Abatacept, Orencia SQ, Secukinumab, Cosentyx, Tofacitinib, Xeljanz, TNF Inhibitor, Etanercept, Certolizumab, Golimumab SQ, Adalimumab, Canakinumab Injection, Ilaris, Baricitinib, Olumiant, Ixekizumab, Taltz | Jeffrey Curtis, University of Alabama at Birmingham, University of Nebraska, University of Pennsylvania, AbbVie, Bristol-Myers Squibb, Novartis, Eli Lilly and Company, Pfizer, Illumination Health | Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis | 04/24 | 05/24 | | |
| Recruiting | 4 | 25 | US | Upadacitinib | Psoriasis Treatment Center of Central New Jersey, AbbVie | Prurigo Nodularis | 12/25 | 01/26 | | |
NCT06520397: Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's Disease |
|
|
| Recruiting | 4 | 214 | RoW | Ustekinumab and Upadacitinib, Ustekinumab | Sixth Affiliated Hospital, Sun Yat-sen University | Crohn Disease | 12/26 | 07/27 | | |
ChiCTR2400090481: A real-world safety study of upadacitinib in Chinese patients with inflammatory bowel disease |
|
|
| Not yet recruiting | 4 | 300 | | No intervention; No intervention | Sir Run Run Shaw Hospital, Zhejiang University School of Medicine; Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Other | Inflammatory bowel disease | | | | |
UP-SPOUT, NCT06454188: A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis |
|
|
| Recruiting | 4 | 100 | Canada, US | Upadacitinib 15 MG [Rinvoq], Rinvoq, Placebo | CARE ARTHRITIS LTD., AbbVie | Psoriatic Arthritis, Spondyloarthritis, Axial | 12/26 | 12/26 | | |
ChiCTR2400085646: A survey of Chinese physicians' preference and clinical use of Upadacitinib |
|
|
| Not yet recruiting | 4 | 300 | | No intervention | Sir Run Run Shaw Hospital, Zhejiang University School of Medicine; Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Other | Inflammatory bowel disease | | | | |
| Not yet recruiting | 4 | 308 | NA | Baricitinib (LY3009104) 4 mg, filgotinib 200mg/day, Tofacitinib 5 mg twice daily, Upadacitinib 15 MG | University Hospital, Toulouse | Rhumatoid Arthisis | 04/29 | 04/29 | | |
| Completed | 4 | 461 | Europe, Canada, Japan, RoW | Upadacitinib, RINVOQ, ABT-494 | AbbVie, AbbVie Inc. | Atopic Dermatitis | 07/24 | 08/24 | | |
BIO3, NCT02714634: Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients with Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide |
|
|
| Recruiting | 4 | 286 | Europe | Methotrexate + targeted therapy administration, methotrexate or leflunomide + sulfasalazine + hydroxychloroquine administration | University Hospital, Strasbourg, France | Rheumatoid Arthritis, Insufficient Response to Methotrexate or Leflunomide | 03/29 | 03/29 | | |
ChiCTR2200066627: Comparison of efficacy and safety between upadacitinib weekend therapy and alternative-day therapy for maintenance treatment of atopic dermatitis: a multicenter, randomized controlled study |
|
|
| Not yet recruiting | 4 | 68 | | upadacitinib 15 mg qd for 2 consecutive days per week till 21 weeks ;upadacitinib 15 mg qod for 12 weeks, follow up till 21 weeks | The Eighth Affiliated Hospital of Sun Yat-sen University (Futian, Shenzhen) ; The Eighth Affiliated Hospital of Sun Yat-sen University (Futian, Shenzhen), The Eighth Affiliated Hospital of Sun Yat-sen University (Futian, Shenzhen) | atopic dermatitis | | | | |
| Not yet recruiting | 4 | 200 | | No intervention | Sir Run Run Shaw Hospital, Zhejiang University School of Medicine; Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Other | Inflammatory bowel disease | | | | |
UP-FOR-U, NCT07018206: Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis |
|
|
| Not yet recruiting | 4 | 200 | US | Upadacitinib 15 MG [Rinvoq] | CARE ARTHRITIS LTD. | Axial Spondylarthritis (axSpA) | 12/26 | 12/26 | | |
ChiCTR2400079755: An open randomized controlled trial of Upadacitinib to improve anxiety in patients with psoriatic arthritis |
|
|
| Recruiting | 4 | 40 | | Upadacitinib (15 mg/day, qd); adalimumab (40 mg/time, once every two weeks) | Shenzhen Traditional Chinese Medicine Hospital, the Fourth Clinical Medical College of Guangzhou University of Chinese Medicine; Shenzhen Traditional Chinese Medicine Hospital, self-finance | Psoriatic arthritis anxiety disorder | | | | |
NCT07258771: Upadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction for Inpatients and Outpatients With Acute Severe Ulcerative Colitis |
|
|
| Not yet recruiting | 4 | 110 | US | Oral Upadacitinib, Rinvoq, Intravenous Methylprednisolone, Solumedrol, Oral Upadacitinib Placebo, Placebo, Oral prednisolone Taper, Prednisone, Oral Prednisone - Hospital Dose Steroids, prednisone | Berinstein, Jeffrey, AbbVie | Ulcerative Colitis Acute | 12/29 | 12/30 | | |
NCT05867329: Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis |
|
|
| Recruiting | 4 | 162 | US | Cyclosporine Injection (IV), Sandimmune, Cyclosporine Oral Product, Upadacitinib Extended Release Oral Tablet, Rinvoq, Intravenous Methylprednisolone, Solu-Medrol, Prednisone Oral Product, Rayos | Berinstein, Jeffrey, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Ulcerative Colitis Acute | 05/26 | 05/26 | | |
ChiCTR2500108912: Real-World Effectiveness and Safety of Upadacitinib in Difficult-to-Treat Crohn’s Disease: A Multicenter Study from China |
|
|
| Recruiting | 4 | 150 | | None | Ruijin Hospital, Shanghai Jiao Tong University School of Medicine; Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, National Key R&D Program of China | Difficult-to-treat CD,DTT-CD | | | | |
ChiCTR2500104153: Comparative Efficacy and Safety of Upadacitinib vs. Tocilizumab in Methotrexate-Inadequate Responders with Moderate-to-Severe Rheumatoid Arthritis |
|
|
| Not yet recruiting | 4 | 40 | | None; None | The Second Hospital of Dalian Medical University; The Second Hospital of Dalian Medical University, Self-finance | Rheumatoid arthritis | | | | |
REACH-AD, ChiCTR2400083248: REal-world utilization and treatment target ACHievement with upadacitinib in adolescents and adults with moderate to severe Atopic Dermatitis in China |
|
|
| Recruiting | 4 | 1000 | | None | Peking Union Medical College Hospital; Peking Union Medical College Hospital, AbbVie Pharmaceutical Trading (Shanghai) Co., Ltd. | Atopic Dermatitis | | | | |
ChiCTR2500103783: A Prospective, Single-Arm, Multicenter, Interventional Study to Evaluate the Efficacy and Safety of Short-term Dual Targeted Therapy of Vedolizumab and Upadacitinib in Participants with Moderate to Severe Active Ulcerative Colitis |
|
|
| Not yet recruiting | 4 | 130 | | Short term combination of vedolizumab and Upatinib, long-term maintenance of vedolizumab | Shanghai Tenth People's Hospital; Shanghai Tenth People's Hospital, Others | active, moderate to severe, UC | | | | |
